{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:03:24Z","timestamp":1782968604479,"version":"3.54.5"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,16]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Immunotherapy with programmed cell death protein-1 (PD-1)\/programmed cell death ligand-1 (PD-L1) inhibitors has been widely used in the treatment of solid tumors and Hodgkin lymphoma, demonstrating powerful efficacy and good safety. However, there is no systematic review and meta-analysis to fully investigate the efficacy and safety of PD-1\/PD-L1 inhibitors in treating non-Hodgkin lymphoma (NHL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched PubMed, EMBASE, The Cochrane Library, China National Knowledge Infrastructure, Wanfang database, and abstracts of conference proceedings of annual meetings up to January 23, 2022, to identify eligible clinical trials. To evaluate the efficacy of PD-1\/PD-L1 inhibitors, objective response rate (ORR), complete response rate (CRR), 1-year overall survival rate, and 1-year progression-free survival rate were analyzed. For safety analysis, we calculated rates of any grade and grade \u22653 treatment-related adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall 22 studies and 1150 participants were enrolled in this meta-analysis. The pooled ORR, CRR, 1-year overall survival, and 1-year progression-free survival rates were 0.43 (95% confidence interval [CI], 0.33\u20130.54), 0.21 (95% CI, 0.13\u20130.31), 0.72 (95% CI, 0.58\u20130.89), and 0.42 (95% CI, 0.29\u20130.62), respectively. The ORR and CRR in the combination immunochemotherapy subgroup (0.65 and 0.41) were higher than those in the monotherapy (0.27 and 0.09) and combination chemotherapy (0.39 and 0.19) subgroups. This study was registered with PROSPERO (#CRD 42022316805).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Given that there were limited clinical trials and relatively few relevant studies, we conducted this meta-analysis to fully elucidate the efficacy and safety of PD-1\/PD-L1 inhibitors in NHL. Our results suggested that PD-1\/PD-L1 inhibitors improved outcomes of responses as well as survival rates in NHL patients with tolerable adverse events. More well-designed randomized clinical trials are still needed to further confirm our findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032333","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:04:29Z","timestamp":1671717869000},"page":"e32333","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials"],"prefix":"10.1097","volume":"101","author":[{"given":"Jiaheng","family":"Guan","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongshu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome.","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial.","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument.","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study.","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study.","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma.","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study.","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma.","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"R16-20250504","first-page":"118","article-title":"Immunochemotherapy in relapsed or refractory B-cell non-hodgkin lymphoma.","volume":"8","author":"Smykova","year":"2019","journal-title":"Cell Ther Transplant"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2019-123978","article-title":"CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody Atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma.","volume":"134","author":"Hutchings","year":"2019","journal-title":"Blood"},{"issue":"SUPPL 1","key":"R18-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136024","article-title":"Safety and efficacy of induction and maintenance avelumab plus RCHOP in patients with diffuse large b-cell lymphoma (DLBCL): analysis of the phase II AVR-CHOP study.","volume":"136","author":"Hawkes","year":"2020","journal-title":"Blood"},{"issue":"SUPPL 2","key":"R19-20250504","first-page":"155","article-title":"9p gain predicts outcomes in patients with relapsed\/refractory (r\/r) diffuse large b-cell lymphoma (DLBCL) treated with r-gemox +\/- atezolizumab. argo: a randomised phase II study.","volume":"39","author":"Davies","year":"2021","journal-title":"Hematol Oncol"},{"issue":"SUPPL 2","key":"R20-20250504","first-page":"135","article-title":"Immune priming with nivolumab followed by nivolumab & rituximab in 1st line treatment of follicular lymphoma: The phase 2 1st FLOR study.","volume":"39","author":"Hawkes","year":"2021","journal-title":"Hematol Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.clml.2021.12.010","article-title":"Combination of atezolizumab and obinutuzumab in patients with relapsed\/refractory follicular lymphoma and diffuse large B-cell lymphoma: results from a phase 1b study.","volume":"22","author":"Palomba","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"SUPPL 2","key":"R22-20250504","first-page":"93","article-title":"Nivolumab plus brentuximab vedotin for relapsed\/refractory primary mediastinal large bcell lymphoma: extended follow-up from the phase 2 checkmate 436 study.","volume":"39","author":"Zinzani","year":"2021","journal-title":"Hematol Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-021-03241-4","article-title":"Safety and efficacy of durvalumab with R-CHOP or R(2)-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.","volume":"115","author":"Nowakowski","year":"2022","journal-title":"Int J Hematol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study.","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2019-125485","article-title":"An update on safety and preliminary efficacy of highly specific Bruton Tyrosine Kinase (BTK) inhibitor Zanubrutinib in combination with PD-1 inhibitor Tislelizumab in patients with previously treated B-cell lymphoid malignancies.","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hon.139_2630","article-title":"Acalabrutinib plus pembrolizumab in relapsed\/refractory diffuse large B-cell lymphoma: a phase 1\/2 study.","volume":"37","author":"Witzig","year":"2019","journal-title":"Hematol Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.25659","article-title":"Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.","volume":"95","author":"Herrera","year":"2020","journal-title":"Am J Hematol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-20-0514","article-title":"Camrelizumab plus gemcitabine, vinorelbine, and pegylated liposomal doxorubicin in relapsed\/refractory primary mediastinal B-cell lymphoma: a single-arm, open-label, phase II trial.","volume":"26","author":"Mei","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"SUPPL 2","key":"R29-20250504","first-page":"298","article-title":"Sintilimab plus chidamide for relapsed\/ refractory (R\/R) extranodal NK\/T cell lymphoma (ENKTL): a prospective, multicenter, single-arm, phase ib\/II trial (SCENT).","volume":"39","author":"Huang","year":"2021","journal-title":"Hematol Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2217\/imt-2016-0080","article-title":"Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.","volume":"8","author":"Marron","year":"2016","journal-title":"Immunotherapy"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.","volume":"128","author":"Tang","year":"2018","journal-title":"J Clin Invest"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas.","volume":"15","author":"Xie","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fimmu.2020.00577","article-title":"4-1BB Agonism combined with PD-L1 blockade increases the number of tissue-resident CD8+ T cells and facilitates tumor abrogation.","volume":"11","author":"Qu","year":"2020","journal-title":"Front Immunol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer.","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","article-title":"Combination therapy with PD-1 or PD-L1 inhibitors for cancer.","volume":"25","author":"Hayashi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2018889931","article-title":"PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.","volume":"133","author":"Pascual","year":"2019","journal-title":"Blood"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"20406207211048959","DOI":"10.1177\/20406207211048959","article-title":"Current and emerging treatment options in primary mediastinal B-cell lymphoma.","volume":"12","author":"Fakhri","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia.","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum Pathol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis.","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40425-018-0427-6","article-title":"Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?","volume":"6","author":"Zhang","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology.","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","article-title":"Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis.","volume":"76","author":"Niglio","year":"2019","journal-title":"Eur Urol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation.","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis.","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"BSR20192347","DOI":"10.1042\/BSR20192347","article-title":"Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.","volume":"40","author":"Shao","year":"2020","journal-title":"Biosci Rep"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity.","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:15:52Z","timestamp":1746332152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":58,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032333","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}